alitretinoin and Dermatitis--Allergic-Contact

Topics: Administration, Oral; Alitretinoin; Azathioprine; Chronic Disease; Dermatitis, Allergic Contact; Dermatologic Agents; Eczema; Hand Dermatoses; Humans; Treatment Outcome

The CARPE registry was set up in 2009 to prospectively investigate the management of patients with chronic hand eczema (CHE).. To report comprehensive follow-up data from the CARPE registry.. We investigated sociodemographic and clinical characteristics, provision of medical care, physician-assessed outcomes, and patient-reported outcomes (PROs). Data were collected between 2009 and 2016, with up to 5 years of follow-up, and are reported descriptively.. Overall, 1281 patients were included in the registry (53.7% female). Mean age was 47.0 years. Of the patients, 793 and 231 completed the 2-year follow-up and 5-year follow-up, respectively. At baseline, 5.4% had changed or given up their job because of CHE, the average duration of CHE was 6.1 years, and, in 22.4%, the CHE was severe according to physician global assessment. Systemic treatment (alitretinoin, acitretin, and methotrexate) was prescribed at least once to 39.0% of the patients during the course of the follow-up. Disease severity, quality of life and treatment satisfaction improved over time, and the proportion of patients receiving systemic treatments decreased.. Under continued dermatological care, substantial improvements in disease severity and PROs over time was achieved during the course of the CARPE registry, even in patients with long-standing and severe hand eczema.

Topics: Acitretin; Administration, Cutaneous; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alitretinoin; Chronic Disease; Dermatitis, Allergic Contact; Dermatologic Agents; Eczema; Female; Follow-Up Studies; Hand Dermatoses; Humans; Male; Methotrexate; Middle Aged; Outcome Assessment, Health Care; Patient Reported Outcome Measures; PUVA Therapy; Registries; Ultraviolet Therapy; Urea; Young Adult

Topics: Adult; Alitretinoin; Cosmetics; Dermatitis, Allergic Contact; Dermatitis, Occupational; Dermatologic Agents; Detergents; Hand Dermatoses; Humans; Male; Occupational Health; Paint; Patch Tests; Pruritus; Recurrence; Secondary Prevention; Steroids; Thiazoles; Treatment Outcome

Hand eczema, which is frequently caused by delayed-type allergy, is treated with 9-cis-retinoic acid (9cisRA). However, knowledge on how 9cisRA modulates skin immunity is sparse.. As dendritic cells (DCs) are central in the pathogenesis of contact allergy, we investigated 9cisRA modulation of DC function in murine contact hypersensitivity (CHS).. 9cisRA-differentiated DCs (9cisRA-DCs) were analysed for phenotype and function. In vivo 9cisRA-DCs were tested in the CHS model.. 9cisRA induces the differentiation of a distinct CD103. This study describes 9cisRA-mediated differentiation of a distinct DC phenotype that relies on OPN for Treg transformation and suppresses established CHS through Treg induction.

Topics: Alitretinoin; Animals; Antigens, CD; Antigens, Surface; Antineoplastic Agents; CD11c Antigen; Cell Differentiation; Cell Proliferation; Cells, Cultured; Culture Media, Conditioned; Dendritic Cells; Dermatitis, Allergic Contact; Histocompatibility Antigens Class II; Hypersensitivity, Delayed; Integrin alpha Chains; Lectins, C-Type; Lymphocyte Activation; Mannose-Binding Lectins; Mice; Mice, Inbred BALB C; Osteopontin; Phenotype; T-Lymphocytes, Regulatory; Tretinoin

Topics: Alitretinoin; Dermatitis, Allergic Contact; Dermatitis, Occupational; Dermatologic Agents; Gardening; Hand Dermatoses; Humans; Male; Middle Aged; Tretinoin